{"id":91889,"date":"2019-06-10T13:42:52","date_gmt":"2019-06-10T20:42:52","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/06\/google-to-spend-billions-developing-gene-therapy-for-heart-disease"},"modified":"2019-06-10T13:42:52","modified_gmt":"2019-06-10T20:42:52","slug":"google-to-spend-billions-developing-gene-therapy-for-heart-disease","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/06\/google-to-spend-billions-developing-gene-therapy-for-heart-disease","title":{"rendered":"Google To Spend Billions Developing Gene Therapy For Heart Disease"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/google-to-spend-billions-developing-gene-therapy-for-heart-disease.jpg\"><\/a><\/p>\n<p>Alphabet, Inc., the parent company of Google, plans to develop a life-long gene therapy for heart disease, the leading cause of death for men and women in the U.S.<\/p>\n<p><a href=\"https:\/\/finance.yahoo.com\/news\/google-jumps-gene-editing-5-131700568.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Attaining this lofty goal<\/a> will be the job of Alphabet\u2019s gene-editing start-up, Verve Therapeutics, and Google\u2019s life science start-up, Verily.<\/p>\n<p>This month, Google\u2019s venture fund, GV, partnered with three other funds to launch Verve Therapeutics with $58.5 million in Series A funding. The company\u2019s scientific founders include Dr. Sekar Kathiresan (CEO), Dr. Kiran Musunuru (chief scientific adviser) and Dr. J. Keith Joung (strategic adviser).<\/p>\n<p><a href=\"https:\/\/www.medicaldaily.com\/google-spend-billions-developing-gene-therapy-heart-disease-434665\" target=\"_blank\" rel=\"noopener noreferrer\"><\/p>\n<div style=\"clear:both;\">Read more<\/div>\n<p><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alphabet, Inc., the parent company of Google, plans to develop a life-long gene therapy for heart disease, the leading cause of death for men and women in the U.S. Attaining this lofty goal will be the job of Alphabet\u2019s gene-editing start-up, Verve Therapeutics, and Google\u2019s life science start-up, Verily. This month, Google\u2019s venture fund, GV, [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-91889","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/91889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=91889"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/91889\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=91889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=91889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=91889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}